Danish Heart Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Copenhagen Denmark (1962)

Organization Overview

First Clinical Trial
1999
NCT00121550
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Danish Heart Foundation | The Danish Heart Foundation, Copenhagen, Denmark

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Atrial Fibrillation (Phase 4)

Cardiovascular Diseases (Phase 3)

Coronary Artery Disease (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Diabetes Mellitus, Type 2 (Phase 3)

Embolism (Phase 4)

Heart Diseases (Phase 3)

Heart Failure (Phase 4)

Hyperglycemia (Phase 2)

Hypertension (Phase 4)

Infarction (Phase 4)

Intermittent Claudication (Phase 4)

Kidney Failure, Chronic (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 3)

Non-ST Elevated Myocardial Infarction (Phase 4)

Pulmonary Embolism (Phase 4)

Renal Insufficiency (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Vascular Diseases (Phase 4)

Venous Thromboembolism (Phase 4)

Venous Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 30